Navigation Links
Boston Scientific to Participate in Merrill Lynch Conference
Date:1/30/2008

NATICK, Mass., Jan. 30 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference, which is being held February 5-7 in New York City.

Paul LaViolette, Chief Operating Officer, will make a 40-minute presentation on Wednesday, February 6, beginning at approximately 10:20 a.m. E.T. Sam Leno, Executive Vice President and Chief Financial Officer will join Mr. LaViolette in a question and answer session.

A live webcast of Mr. LaViolette's remarks and the question and answer session will be available to all interested parties at Boston Scientific's website at http://www.bostonscientific.com. Please visit the website for details on how to access the webcast. To ensure a timely connection to the webcast it is recommended that users register at least 15 minutes before the webcast begins.

This webcast is being hosted by Merrill Lynch. The replay will be archived and available in the Investor Relations site at http://www.bostonscientific.com.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Dan Brennan

508-650-8538 (office)

Investor Relations

Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
2. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
3. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
4. Boston Scientific Announces Results for Third Quarter Ended September 30, 2007
5. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
6. The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-6
7. Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator
8. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
9. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
10. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
11. Genzyme Begins Major Expansion of Boston Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/24/2016)... -- Regular discussions on a range of subjects including policies, debt ... said Poloz. Speaking at a lecture to the ... pointed to the country,s inflation target, which is set by ... "In certain areas there needs to ... goals, why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
Breaking Biology Technology:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
Breaking Biology News(10 mins):